Here's What Pressured Allegiant Travel Company (ALGT) in Q1
Diamond Hill Capital, an investment management company, released its 'Small Cap Fund' first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q1, markets were uneven due to the new presidential administration's activity, leading to concern about the future. The Russell 3000 Index fell by 4.7% in Q1, the first quarterly loss since Q3 2023. Diamond Hill Small Cap Fund returned -11.56% in Q1, trailing the Russell 2000 Index's -9.48% return. For more information on the fund's top picks in 2025, please check its top five holdings.
In its first-quarter 2025 investor letter, Diamond Hill Small Cap Fund highlighted stocks such as Allegiant Travel Company (NASDAQ:ALGT). Based in Las Vegas, Nevada, Allegiant Travel Company (NASDAQ:ALGT) is a leisure travel company. The one-month return of Allegiant Travel Company (NASDAQ:ALGT) was 1.85%, and its shares lost 6.88% of their value over the last 52 weeks. On May 6, 2025, Allegiant Travel Company (NASDAQ:ALGT) stock closed at $49.41 per share with a market capitalization of $901.965 billion.
Diamond Hill Small Cap Fund stated the following regarding Allegiant Travel Company (NASDAQ:ALGT) in its Q1 2025 investor letter:
"Other bottom Q1 contributors included First Advantage, Civitas Resources and Allegiant Travel Company (NASDAQ:ALGT). Regional airline Allegiant Travel fell against a challenging macroeconomic backdrop and concerns about consumer spending, which could hurt customer demand. Further, there are some concerns the recently announced US tariffs could impact Boeing's ability to deliver new planes to Allegiant as expected. However, we maintain our conviction in Allegiant's resiliency in the long term and are maintaining our position."
Is Allegiant Travel Company (ALGT) the Best Airline Stock to Buy Now?
A busy airport terminal with travelers passing through on their leisure travels.
Allegiant Travel Company (NASDAQ:ALGT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 20 hedge fund portfolios held Allegiant Travel Company (NASDAQ:ALGT) at the end of the fourth quarter, compared to 15 in the third quarter. While we acknowledge the potential of Allegiant Travel Company (NASDAQ:ALGT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we covered Allegiant Travel Company (NASDAQ:ALGT) and shared the list of best airline stocks to buy. In the previous quarter investor letter, Diamond Hill Small Cap Fund discussed Allegiant Travel Company (NASDAQ:ALGT), highlighting its rise as concerns eased—particularly following the resolution of the Boeing strike. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ('Gyre') (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A ('ETA') receptor antagonist, for the treatment of pulmonary arterial hypertension ('PAH').This milestone marks Gyre's entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China's National Rare Disease Catalog, underscoring its significance in public health. According to Frost & Sullivan, China's PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre's fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.F230 joins Gyre's pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application ('NDA') submission to China's National Medical Products Administration ('NMPA') is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis ('MASH') Gyre TherapeuticsGyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre's strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People's Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre's research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'plan' or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre's ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre's capital resources and its ability to raise additional capital. Additional risks and factors are identified under 'Risk Factors' in Gyre's Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by Contact:David ZhangGyre in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
26 minutes ago
- Business Wire
Leap and Xos Partner to Power the Grid with Electric Fleets
SAN FRANCISCO & LOS ANGELES--(BUSINESS WIRE)-- Leap, the leading platform for building and scaling virtual power plants (VPPs), and Xos, Inc., (NASDAQ:XOS), a leading electric truck manufacturer and fleet services provider, today announced a new partnership to unlock grid revenue opportunities for electrified fleets. By connecting Xos Hub charging technology to energy markets through Leap's automated platform, the companies will create new value for fleet owners and deliver crucial support for the grid during energy emergencies. By connecting Xos Hub charging technology to energy markets through Leap's automated platform, the companies will create new value for fleet owners and deliver crucial support for the grid during energy emergencies. Share Xos manufactures electric stepvan vehicles used by some of the country's most recognizable logistics companies, including FedEx and UPS. The company's Xos Hub is a mobile, battery-integrated charger designed to speed up fleet electrification without the delays or costs of traditional infrastructure. It provides a versatile, scalable solution for stopgap charging, remote deployments, semi-permanent charging, and backup power. Now, by using Leap's software-only VPP platform, Xos can enroll its customers in California's Demand Side Grid Support (DSGS) grid services program. During emergency grid events, participating fleets will automatically shift charging from the grid to their Xos Hub battery-integrating chargers, relieving grid strain while generating revenue. Last summer, with major contributions from Leap, DSGS helped California avoid blackouts during prolonged heatwaves. With the addition of Xos's rapidly growing portfolio, Leap and its partners are poised to scale their impact and deliver even greater support to the grid. 'Leveraging our complementary technologies, Leap and Xos are tapping new value streams for commercial truck fleets, the transportation services that power our economy,' said Jason Michaels, CEO of Leap. 'Together, we're making these fleets cleaner, smarter, and more cost effective, while contributing to a more resilient energy landscape.' Leap's universal API suite automates energy market operations, enabling Xos to quickly deploy and scale its own VPP offering without additional hardware or significant additional operational overhead. This means that Xos can immediately start generating new grid revenue, reducing the total product cost for customers and driving ongoing energy savings. 'Our VPP offering gives fleet customers advanced energy capabilities without compromising control or convenience,' said Dakota Semler, CEO of Xos, Inc. 'It's a powerful way to lower the cost of infrastructure ownership even further, maximize the value of our products, and support customers in meeting their electrification goals.' About Leap Leap is the leading platform for launching and scaling virtual power plants (VPPs). Through its software-only solution, Leap facilitates fast, easy and automated access to demand response and other grid services revenue streams for the providers of battery storage systems, EV chargers, smart building technologies, and other distributed energy resources (DERs). Managing over 200,000 energy sites and devices across U.S. energy markets, Leap empowers more than 90 technology partners and their customers to unlock new value and help create a more flexible, resilient grid powered by renewable resources. Visit to learn more. About Xos, Inc. Xos is a leading technology company, electric truck manufacturer, and fleet services provider for battery-electric fleets. Xos vehicles and fleet management software are purpose-built for medium- and heavy-duty commercial vehicles that travel on last-mile, back-to-base routes. The company leverages its proprietary technologies to provide commercial fleets with battery-electric vehicles that are easier to maintain and more cost-efficient on a total cost of ownership (TCO) basis than their internal combustion engine counterparts. For more information, visit
Yahoo
an hour ago
- Yahoo
Baird Cuts Tesla to Hold as Musk's Role, Robotaxi Hype Create Uncertainty
Tesla (NASDAQ:TSLA) just got a reality check from one of its long-time bulls. Robert W. Baird analyst Ben Kallo downgraded the stock from Buy to Hold his first such move in three years. While the firm is still sticking to its $320 price target, that's a slight drop from where Tesla's currently trading. In other words, Baird doesn't see much short-term upside right now. Why the shift? Kallo pointed to growing hype around Tesla's upcoming robotaxi event. He thinks expectations may be running a bit too hot, especially considering the company was only just added to Austin's autonomous vehicle testing registry. By comparison, Alphabet's (NASDAQ:GOOG) Waymo is already in the deployment phase. There's also what Kallo calls key-man risk. That's a reference to Elon Musk, whose influence at Tesla is massive. His recent public support for Donald Trump and involvement in political discourse is creating more uncertainty, not less at least from an investor perspective. Interestingly, Tesla shares were up about 3% in premarket trading. That may reflect cooling tensions between Musk and Trump, with reports that the president plans to keep his Tesla and Starlink setup if he returns to the White House. Kallo still sees Tesla as a long-term player, but for now, he's urging caution. Other factors like tougher EV competition, shifting delivery estimates, and possible changes to tax incentives are also in the mix. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
